Yang T S, Tsan S H, Chen C R, Chang S P, Ng H T
Department of Obstetrics and Gynecology, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Zhonghua Yi Xue Za Zhi (Taipei). 1996 Aug;58(2):89-96.
An oral synthetic 19 norsteroid (gestrinone) characterized by antigonadotropic activity and antioestrogenic properties provides its use in the treatment of oestrogen depending pathologic conditions. The purpose of this open study is to evaluate the efficacy and tolerance of gestrinone in the treatment of endometriosis.
Twenty premenopausal women with laparoscopically confirmed endometriosis received 2.5 mg gestrinone two times per week for six months. Laparoscopy was performed before treatment, and clinical responses were determined by second laparoscopy after six months. Serum CA-125 level, plasma lipid and bone density measurements during and after therapy were compared with baseline.
The mean endometriosis score, defined by the revised American Fertility Society scoring system, decreased from 20.16 to 4.68 (p < 0.01). The mean serum level of CA-125 also declined from 44.04 U/ml to 18.64 U/ml (p < 0.01). Metabolic studies showed a significant decrease of cholesterol in high-density lipoprotein (p < 0.05), a moderate increase in low-density lipoprotein (p > 0.05), and a slight increase in both triglyceride and total cholesterol levels (p > 0.05). Bone density in this study also showed no significant difference in either spine or femur neck for a duration of six months treatment. Hot flush occurred in less frequency in gestrinonetreated group than in gonadotropin releasing hormone agonist (GnRHa-treated group), where the side effects of weight gain and acne were less often than in the danazol group well.
Gestrinone 2.5 mg given twice a week for six months provides an effective and safe treatment for those women suffering from endometriosis.
一种具有抗促性腺激素活性和抗雌激素特性的口服合成19-去甲甾体（孕三烯酮）可用于治疗依赖雌激素的病理状况。这项开放性研究的目的是评估孕三烯酮治疗子宫内膜异位症的疗效和耐受性。
20名经腹腔镜确诊为子宫内膜异位症的绝经前女性，每周服用2次2.5mg孕三烯酮，持续6个月。治疗前进行腹腔镜检查，6个月后通过第二次腹腔镜检查确定临床反应。将治疗期间及治疗后的血清CA-125水平、血脂和骨密度测量结果与基线进行比较。
根据修订的美国生育协会评分系统定义的平均子宫内膜异位症评分从20.16降至4.68（p<0.01）。血清CA-125的平均水平也从44.04U/ml降至18.64U/ml（p<0.01）。代谢研究显示，高密度脂蛋白中的胆固醇显著降低（p<0.05），低密度脂蛋白适度升高（p>0.05），甘油三酯和总胆固醇水平略有升高（p>0.05）。在为期6个月的治疗期间，本研究中的骨密度在脊柱或股骨颈方面也未显示出显著差异。孕三烯酮治疗组潮热发生频率低于促性腺激素释放激素激动剂（GnRHa）治疗组，体重增加和痤疮等副作用也比达那唑组少。
每周服用2次2.5mg孕三烯酮，持续6个月，为患有子宫内膜异位症的女性提供了一种有效且安全的治疗方法。
